Ahmedabad doctors save Nigerian lawyer’s eye – Times of India
Ahmedabad doctors save Nigerian lawyer's eye Times of India Gbenga's left eye had developed antibodies which led to 'sympathetic opthalmia'- a very rare and serious eye disease. The antibodies that were produced when he lost his vision to measles were now misdirected against his good eye and were out to turn ... |
‘Schizophrenia Risk In Kids Associated With Mothers’ Gluten Antibodies’ – Medical News Today
 PsychCentral.com | 'Schizophrenia Risk In Kids Associated With Mothers' Gluten Antibodies' Medical News Today The team used stored neonatal blood samples in order to measure levels of IgG antibodies to milk and wheat. They found that children born to mothers with abnormally high levels of antibodies to the wheat protein gluten were nearly 50% more likely to ... Gluten and Schizophrenia Linked Gluten Sensitivity in Mothers Linked to Schizophrenia Risk in Children |
Is Dose-Dense Therapy Effective Against DLBCL in the Era of Rituximab? – Cancer Network
Is Dose-Dense Therapy Effective Against DLBCL in the Era of Rituximab? Cancer Network The authors asked whether there is still debate surrounding dose intensity since the introduction of the monoclonal antibody rituximab (Rituxan [R]), which has improved the clinical outcomes of patients with DLBCL. The focus of the review addressed the ... |
Viropro, Inc. to Unlock Value from its Biosimilars Portfolio – Genetic Engineering News (press release)
Viropro, Inc. to Unlock Value from its Biosimilars Portfolio Genetic Engineering News (press release) It is from this portfolio that Viropro signed a Letter of Agreement with Spectrum Pharmaceuticals, Inc. for Rituximab, and is in active discussions with potential clients for its other biosimilar technologies. (“®” are registered trademarks of their ... |
Viropro, Inc. to Unlock Value from its Biosimilars Portfolio – MarketWatch (press release)
Viropro, Inc. to Unlock Value from its Biosimilars Portfolio MarketWatch (press release) The starting line-up and portfolio consists of sophisticated biosimilar molecules such as Ranibizumab (biosimilar of Lucentis(R)), Trastuzumab (-Herceptin(R)), Rituximab (-Rituxan(R)), Bevacizumab (-Avastin(R)), Infliximab (-Remicade(R)) and Etanercept ... |
Intellect Neurosciences Expands Its Immunotherapy Pipeline with New Technology … – MarketWatch (press release)
Intellect Neurosciences Expands Its Immunotherapy Pipeline with New Technology ... MarketWatch (press release) Company Files Three Patent Applications for Methods of Diagnosis and Treatment of Neurodegenerative Diseases Based on Production of Antibodies, and Vaccines that Selectively Target the Earliest Forms of Neurotoxic Proteins. NEW YORK, May 16, ... Intellect Neurosciences Issues Letter to Shareholders |
5W Public Relations Hired by IMMUNE Pharmaceuticals – Everything PR
 Everything PR | 5W Public Relations Hired by IMMUNE Pharmaceuticals Everything PR An emerging leader in monoclonal antibodies, IMMUNE will receive 5WPR's comprehensive public relations program that targets influential media. 5WPR's President and CEO, Ronn Torossian, says his company aims to: “[increase] awareness of IMMUNE and its ... |
Global Laboratory Chemical Reagents Industry – MarketWatch (press release)
Global Laboratory Chemical Reagents Industry MarketWatch (press release) This report analyzes the worldwide markets for Laboratory Chemical Reagents in US$ Million by the following Product Segments: Molecular Biology (Monoclonal & Polyclonal Antibodies, Gene Expression, Vectors, Cloning, & Sequencing, Gene Synthesis, ... |
Targeted Cancer Drugs With Punch: The Next Big Class of Antibodies – Xconomy
Targeted Cancer Drugs With Punch: The Next Big Class of Antibodies Xconomy Yet it's only been in the last several years that a couple of companies—Seattle Genetics and Genentech—have shown proof in clinical trials that they can go a step further than what's been done with so-called “naked” antibodies. The concept is simple: ... |
Biosceptre, University of Queensland to collaborate on cancer antibodies – Australian Life Scientist
Biosceptre, University of Queensland to collaborate on cancer antibodies Australian Life Scientist Biosceptre and the University of Queensland's AIBN research institute have teamed up to develop a production method for monoclonal antibodies designed to trigger cancer cell death. Biosceptre International has entered into a cancer treatment research ... |